logo
  

Rockwell Automation Boosts FY21 Outlook - Quick Facts

While reporting financial results for the third quarter on Tuesday, Rockwell Automation, Inc. (ROK) raised its adjusted earnings and sales growth guidance for the full-year 2021, based on the performance through the first three quarters of the year, expectation of continued orders strength, and anticipation of continued supply chain constraints.

For fiscal 2021, the company now projects adjusted earnings in a range of $9.10 to $9.30 per share on reported sales growth of about 12 percent and organic sales growth of 8 percent.

Previously, the company expects adjusted earnings in the range of $8.95 to $9.35 per share on reported sales growth of 9 to 12 percent and organic sales growth 5.5 to 8.5 percent.

On average, 24 analysts polled by Thomson Reuters expect the company to earn $9.24 per share on a revenue growth of 10.7 percent to $7.01 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT